Ocugen, Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing modifier gene therapies for retinal diseases. Form 8-K disclosures cover clinical and Regulation FD updates for programs including OCU410, capital-structure events such as warrant exercises and 6.75% convertible senior notes due 2034, and material agreements tied to the note indenture and loan repayment.
Proxy materials describe annual meeting proposals, shareholder voting matters, and governance practices. Other filings identify the company's common stock on The Nasdaq Capital Market, preliminary financial information, authorized-share validation matters, and furnished investor presentations containing forward-looking clinical-development statements.
Ocugen, Inc. is asking stockholders to approve an amendment to its charter to increase authorized common stock by 250,000,000 shares, from 390,000,000 to 640,000,000, at a virtual special meeting on September 21, 2026. As of the July 27, 2026 record date, 339,110,401 common shares were outstanding, each entitled to one vote.
The Board cites needs for future equity financing, business combinations, and equity incentives, and to support potential share settlement of $130.0 million of 6.75% convertible senior notes due 2034, which require sufficient authorized but unissued shares by September 30, 2026. Ocugen acknowledges that issuing additional shares could dilute earnings per share and voting power and may have anti-takeover effects, though it states the proposal is not intended as a takeover defense. A second proposal would allow adjournment of the meeting to solicit additional proxies if votes for the share increase are initially insufficient.
BlackRock, Inc. reports beneficial ownership of 26,952,492 shares of Ocugen, Inc. common stock, representing 8.0% of the class. These shares correspond to the CUSIP 67577C105 and are held across certain reporting business units of BlackRock and its subsidiaries.
BlackRock has sole voting power over 26,625,805 shares and sole dispositive power over 26,952,492 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends and sale proceeds, but no single person holds more than 5% of Ocugen’s outstanding common shares.
Ocugen, Inc. is asking stockholders at a September 21, 2026 virtual special meeting to approve an amendment to its charter increasing authorized common stock by 250,000,000 shares, from 390,000,000 to 640,000,000, while keeping 10,000,000 preferred shares authorized. The board unanimously approved and recommends this change.
The company states the added capacity is intended to support potential equity and convertible financings, business combinations, collaborations, and equity incentive compensation, and to help fund its pipeline, including plans for three BLA submissions by 2028. Ocugen highlights that issuing new shares later could dilute earnings per share and voting power and could under some circumstances have anti-takeover effects, though it says the proposal is not in response to any takeover effort.
The filing also notes $130.0 million of 6.75% convertible senior notes due 2034, with covenants requiring a stockholder vote by September 30, 2026 to ensure sufficient authorized and unissued shares for potential conversion; absent approval, conversions must initially be settled in cash. A second proposal would allow adjournment of the meeting to solicit additional proxies if votes for the share increase are insufficient.
Ocugen, Inc. has signed a binding term sheet with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding to negotiate an exclusive license for OCU400 modifier gene therapy for Retinitis Pigmentosa in the Middle East and North Africa. Under the contemplated license, Ocugen expects upfront and near-term development milestone payments totaling up to $4 million, potential sales milestone payments up to $255 million, and a 22% royalty on net sales of OCU400 in the territory. Ocugen would also supply commercial product under a related supply agreement. A definitive agreement is expected within 90 days. OCU400 is being evaluated in the Phase 3 liMeliGhT program, with topline data anticipated in 1Q 2027 followed by a planned BLA submission.
Ocugen, Inc. Chief Financial Officer Treerita Essalima Johnson-Greene bought 21,000 shares of Common Stock in an open-market purchase at $1.23 per share. Following this transaction, she directly holds 521,000 shares and has indirect ownership of 350 shares held by her spouse.
Ocugen, Inc. director Uday Kompella received a grant of stock options covering 170,100 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 11, 2036.
The award vests upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, provided he continues serving through the vesting date. Following this grant, Kompella holds 170,100 options directly.
Ocugen, Inc. director Chandrasekhar Satishchandran received a grant of stock options covering 170,100 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 11, 2036.
The award vests upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, subject to his continued service through the vesting date. After this grant, his reported derivative holdings in this award total 170,100 options.
Ocugen, Inc. director Kirsten Castillo received a grant of stock options as equity compensation. The award covers 170,100 options to buy common stock at an exercise price of $1.22 per share, expiring on June 11, 2036.
The options vest upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, provided she continues to serve through the vesting date. Following this grant, she holds 170,100 derivative securities related to common stock.
Ocugen, Inc. director Junge Zhang received a grant of stock options on June 11, 2026 as part of equity compensation. The award covers 170,100 options to buy common stock at an exercise price of $1.22 per share, expiring on June 11, 2036. The options vest on the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, contingent on continued service through the vesting date. Following this grant, the filing shows Zhang holding 170,100 derivative securities directly, with no open‑market purchases or sales reported.
Ocugen, Inc. director Blaise Coleman received a new stock option grant covering 170,100 shares of common stock. The option has an exercise price of $1.22 per share and expires on June 11, 2036. This is a compensation-related award, not an open-market purchase.
According to the terms, the option vests upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, provided Coleman continues to serve through the applicable vesting date. Following this grant, he holds 170,100 stock options directly.